Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
about
Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?Research in the heart of hematology: chronic myeloid leukemia 2017.Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.Sex chromosome changes in leukemia: cytogenetics and molecular aspects.Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.A Rare Monocytic Crisis of Chronic Myelogenous Leukemia Presenting with Unusual Extramedullary Manifestations and an Atypical (14;22)(q24;q11.2) Translocation in the Bone Marrow.3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.Recurrent Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Chronic Myeloid Leukemia.Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Constitutional t(8;22)(q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosome-positive chronic myeloid leukemia.Cytogenetic alterations in CML: not all created equal.Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860
Q37490012-AE794F98-826F-464C-8A33-11C7753E51B7Q40607863-041BB33D-3151-41ED-B995-CBBC3E887BE0Q41316578-0D54C5D8-019F-4D9C-86B7-A6D31CE82D3BQ42349210-13687672-3B9F-4962-B079-3702CBBB4B86Q42361988-8B3D166D-B5FC-4A64-950A-28B9930E4344Q47659016-2CF33578-6326-42EE-AF57-36C3EEA69F57Q47693182-9AE1BD33-F795-4F2C-B67A-02091A8FF1ECQ48029219-929EBBA8-9C91-4E1D-B571-5322A8EE76E4Q48152735-71569D82-834C-496C-B39B-4B3F0FF38B05Q48171349-7D785362-A238-4A75-926F-E6CB181BCBA3Q48186139-48EEDA8C-71B0-4632-AA96-192D68864845Q50095934-FF3D36E4-4AD7-4634-B454-42E461D8CB95Q50776559-9F7430ED-A6AF-4A24-B613-C7B582327FBFQ51032313-C587496B-6286-4FFF-8C16-1A735C1C5694Q51286694-495E14A1-64AE-42C4-B213-3FF34CD18F38Q52675422-5DB9A2A7-D3A2-480C-A8E7-9C0A1F3EA83DQ54963575-8C0AB860-2284-41F5-AA2C-A54C4CECC93BQ55362356-4A98DED0-55C5-41F5-B2B3-9BF1336A243F
P2860
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@en
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@nl
type
label
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@en
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@nl
prefLabel
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@en
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@nl
P2093
P2860
P1433
P1476
Risk stratification of chromos ...... sine kinase inhibitor therapy.
@en
P2093
Carlos E Bueso-Ramos
Guilin Tang
Joseph A DiGiuseppe
Joseph D Khoury
L Jeffrey Medeiros
P2860
P304
P356
10.1182/BLOOD-2016-01-690230
P407
P577
2016-03-22T00:00:00Z